562 related articles for article (PubMed ID: 26560119)
21. Targeting the ubiquitin pathway for cancer treatment.
Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
[TBL] [Abstract][Full Text] [Related]
22. Regulation of SCF(SKP2) ubiquitin E3 ligase assembly and p27(KIP1) proteolysis by the PTEN pathway and cyclin D1.
Jonason JH; Gavrilova N; Wu M; Zhang H; Sun H
Cell Cycle; 2007 Apr; 6(8):951-61. PubMed ID: 17438373
[TBL] [Abstract][Full Text] [Related]
23. A cell-based high-throughput screening method based on a ubiquitin-reference technique for identifying modulators of E3 ligases.
Tian M; Zeng T; Liu M; Han S; Lin H; Lin Q; Li L; Jiang T; Li G; Lin H; Zhang T; Kang Q; Deng X; Wang HR
J Biol Chem; 2019 Feb; 294(8):2880-2891. PubMed ID: 30587574
[TBL] [Abstract][Full Text] [Related]
24. Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis.
Choi HH; Guma S; Fang L; Phan L; Ivan C; Baggerly K; Sood A; Lee MH
Cell Cycle; 2015; 14(14):2265-73. PubMed ID: 25945542
[TBL] [Abstract][Full Text] [Related]
25. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].
Daks AA; Melino D; Barlev NA
Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121
[TBL] [Abstract][Full Text] [Related]
26. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].
Yu Q; Xiong X; Sun Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):1-19. PubMed ID: 32621419
[TBL] [Abstract][Full Text] [Related]
27. Skp2 in the ubiquitin-proteasome system: A comprehensive review.
Asmamaw MD; Liu Y; Zheng YC; Shi XJ; Liu HM
Med Res Rev; 2020 Sep; 40(5):1920-1949. PubMed ID: 32391596
[TBL] [Abstract][Full Text] [Related]
28. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
Liu L; Wong CC; Gong B; Yu J
Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
[TBL] [Abstract][Full Text] [Related]
29. Modification of cullin-1 by ubiquitin-like protein Nedd8 enhances the activity of SCF(skp2) toward p27(kip1).
Morimoto M; Nishida T; Honda R; Yasuda H
Biochem Biophys Res Commun; 2000 Apr; 270(3):1093-6. PubMed ID: 10772955
[TBL] [Abstract][Full Text] [Related]
30. NEDD4: a promising target for cancer therapy.
Ye X; Wang L; Shang B; Wang Z; Wei W
Curr Cancer Drug Targets; 2014; 14(6):549-56. PubMed ID: 25088038
[TBL] [Abstract][Full Text] [Related]
31. Regulation of TGF-beta family signaling by E3 ubiquitin ligases.
Inoue Y; Imamura T
Cancer Sci; 2008 Nov; 99(11):2107-12. PubMed ID: 18808420
[TBL] [Abstract][Full Text] [Related]
32. High expression of Pirh2, an E3 ligase for p27, is associated with low expression of p27 and poor prognosis in head and neck cancers.
Shimada M; Kitagawa K; Dobashi Y; Isobe T; Hattori T; Uchida C; Abe K; Kotake Y; Oda T; Suzuki H; Hashimoto K; Kitagawa M
Cancer Sci; 2009 May; 100(5):866-72. PubMed ID: 19445020
[TBL] [Abstract][Full Text] [Related]
33. p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway.
Pamarthy D; Tan M; Wu M; Chen J; Yang D; Wang S; Zhang H; Sun Y
Cancer Biol Ther; 2007 Mar; 6(3):360-6. PubMed ID: 17312389
[TBL] [Abstract][Full Text] [Related]
34. Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells.
Rico-Bautista E; Yang CC; Lu L; Roth GP; Wolf DA
BMC Biol; 2010 Dec; 8():153. PubMed ID: 21182779
[TBL] [Abstract][Full Text] [Related]
35. Targeting E3 ubiquitin ligases for cancer therapy.
Sun Y
Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells.
Lu Y; Zi X; Pollak M
Int J Cancer; 2004 Jan; 108(3):334-41. PubMed ID: 14648698
[TBL] [Abstract][Full Text] [Related]
37. Virtual drug design: Skp1-Skp2 inhibition targets cancer stem cells.
Pascal LE; Wang Z
Asian J Androl; 2013 Nov; 15(6):717-8. PubMed ID: 24077600
[TBL] [Abstract][Full Text] [Related]
38. Skp2 is oncogenic and overexpressed in human cancers.
Gstaiger M; Jordan R; Lim M; Catzavelos C; Mestan J; Slingerland J; Krek W
Proc Natl Acad Sci U S A; 2001 Apr; 98(9):5043-8. PubMed ID: 11309491
[TBL] [Abstract][Full Text] [Related]
39. The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.
Jamal A; Swarnalatha M; Sultana S; Joshi P; Panda SK; Kumar V
Cell Cycle; 2015; 14(16):2688-700. PubMed ID: 26038816
[TBL] [Abstract][Full Text] [Related]
40. Skp2-mediated p27(Kip1) degradation during S/G2 phase progression of adipocyte hyperplasia.
Auld CA; Fernandes KM; Morrison RF
J Cell Physiol; 2007 Apr; 211(1):101-11. PubMed ID: 17096381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
